Farrugia Frederick-Anthony, Zavras Nicolaos, Martikos Georgios, Tzanetis Panagiotis, Charalampopoulos Anestis, Misiakos Evangelos P, Sotiropoulos Dimitrios, Koliakos Nikolaos
1General Surgeon, Private practice, Athens, Greece.
2Associate Professor of Pediatric Surgery, Department of Pediatric Surgery, Attikon University Hospital, University of Athens School of Medicine, Athens, Greece.
Endocr Regul. 2018 Jan 1;52(1):27-40. doi: 10.2478/enr-2018-0005.
The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension. It has been reported up to 24% of selective referred hypertensive patients.
We did a search in Pub-Med and Google Scholar using the terms: PA, hyperaldosteronism, idiopathic adrenal hyperplasia, diagnosis of PA, mineralocorticoid receptor antagonists, adrenalectomy, and surgery. We also did cross-referencing search with the above terms. We had divided our study into five sections: Introduction, Diagnosis, Genetics, Treatment, and Conclusions. We present our results in a question and answer fashion in order to make reading more interesting.
PA should be searched in all high-risk populations. The gold standard for diagnosis PA is the plasma aldosterone/plasma renin ratio (ARR). If this test is positive, then we proceed with one of the four confirmatory tests. If positive, then we proceed with a localizing technique like adrenal vein sampling (AVS) and CT scan. If the lesion is unilateral, after proper preoperative preparation, we proceed, in adrenalectomy. If the lesion is bilateral or the patient refuses or is not fit for surgery, we treat them with mineralocorticoid receptor antagonists, usually spironolactone.
Primary aldosteronism is the most common and a treatable case of secondary hypertension. Only patients with unilateral adrenal diseases are eligible for surgery, while patients with bilateral and non-surgically correctable PA are usually treated by mineralocorticoid receptor antagonist (MRA). Thus, the distinction between unilateral and bilateral aldosterone hypersecretion is crucial.
本研究旨在提供有关原发性醛固酮增多症(PA)诊断和治疗的最新信息。PA是内分泌性高血压最常见的病因。据报道,在选择性转诊的高血压患者中,PA的比例高达24%。
我们在PubMed和谷歌学术上使用以下术语进行搜索:PA、醛固酮增多症、特发性肾上腺增生、PA的诊断、盐皮质激素受体拮抗剂、肾上腺切除术和手术。我们还使用上述术语进行了交叉引用搜索。我们将研究分为五个部分:引言、诊断、遗传学、治疗和结论。我们以问答的形式呈现结果,以使阅读更有趣。
应在所有高危人群中筛查PA。诊断PA的金标准是血浆醛固酮/血浆肾素比值(ARR)。如果该测试呈阳性,那么我们进行四项确诊测试之一。如果呈阳性,那么我们进行肾上腺静脉采样(AVS)和CT扫描等定位技术。如果病变是单侧的,经过适当的术前准备后,我们进行肾上腺切除术。如果病变是双侧的,或者患者拒绝或不适合手术,我们用盐皮质激素受体拮抗剂,通常是螺内酯进行治疗。
原发性醛固酮增多症是继发性高血压最常见且可治疗的病例。只有单侧肾上腺疾病患者适合手术,而双侧和无法通过手术纠正的PA患者通常用盐皮质激素受体拮抗剂(MRA)治疗。因此,区分单侧和双侧醛固酮分泌过多至关重要。